
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc has developed a proprietary PREDATOR platform that enables the creation of conditionally activated molecules, designed to selectively stimulate the immune system within the tumor microenvironment, thus enhancing both safety and efficacy in cancer treatments. The positive clinical results from its lead asset WTX-124, which has demonstrated promising tolerability and anti-tumor activity in solid tumors, alongside favorable outcomes from WTX-330 and other INDUKINE programs, signal a de-risked development pathway for the company's future oncology and immune-mediated therapies. Additionally, the capacity of Werewolf's therapy to mitigate systemic toxicity while delivering significantly greater doses than traditional therapies reinforces the positive outlook, indicating potential for greater market acceptance and expansion into new therapeutic areas.
Bears say
Werewolf Therapeutics Inc. reported a significant net loss of $20.4 million, or $0.46 per share, for the fourth quarter of 2024, which is notably higher than the $12.0 million loss recorded in the same quarter of the previous year. The company faces considerable risks regarding its WTX-124 program, as potential clinical or regulatory setbacks could hinder its progress and affect revenue estimates if the treatment is approved. Additionally, concerns regarding the safety, efficacy, and pharmacokinetic properties of WTX-124, along with potential competition from existing and emerging therapies, contribute to a negative outlook on the company's financial prospects.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares